Welcome to our dedicated page for Annexon SEC filings (Ticker: ANNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Annexon SEC filings document a clinical-stage biopharmaceutical company developing C1q-targeted immunotherapies for neuroinflammatory and classical complement-mediated diseases. Its Form 8-K reports furnish operating results, portfolio progress, investor presentations, and strategic priority updates tied to programs such as vonaprument, tanruprubart, and ANX1502.
The company’s filings also cover proxy governance, annual meeting proposals, director elections, auditor ratification, executive compensation votes, board changes, and Nasdaq-listed common stock. Capital-structure disclosures include amendments to common stock purchase warrants and related rights of security holders.
Annexon, Inc. (ANNX) received an updated ownership report from investment firm Redmile Group, LLC, its principal Jeremy C. Green, and fund Redmile Biopharma Investments II, L.P. They report beneficial ownership of 15,427,866 shares of common stock, or 9.9% of the class.
This total includes 10,050,644 existing shares held for Redmile-managed clients and up to 5,377,222 shares issuable from pre-funded warrants, subject to a 9.99% Beneficial Ownership Limitation. RBI II separately reports 7,288,917 shares, or 4.7% of the class, combining directly held shares and warrants within the same cap. The filers certify the holdings are not for the purpose of changing or influencing control of Annexon.
FMR LLC has filed Amendment No. 5 to a Schedule 13G/A reporting its beneficial ownership in Annexon Inc. common stock. As of the event date of 12/31/2025, FMR LLC and related entities report beneficial ownership of 10,222,470.36 shares, representing 7.1% of Annexon’s common stock.
FMR LLC has sole voting power over 10,216,569 shares and sole dispositive power over 10,222,470.36 shares, with no shared voting or dispositive power. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Annexon.
BlackRock, Inc. filed an amended ownership report showing it beneficially owns 8,868,755 shares of ANNEXON INC common stock, representing 6.1% of the class as of the event date 12/31/2025. BlackRock reports sole power to vote 8,773,698 shares and sole power to dispose of 8,868,755 shares, with no shared voting or dispositive power.
The filing explains that these holdings are attributed to certain BlackRock business units, and that various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of Annexon’s outstanding common shares. BlackRock certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Annexon.
Annexon, Inc. reported that it has updated its corporate investor presentation to reflect certain business and strategic updates. The revised presentation, dated January 14, 2026, may be used in upcoming meetings with analysts and investors, including at the 44th Annual J.P. Morgan Healthcare Conference. It will also be available in the Investors & Media section of the company's website.
The investor presentation is furnished as Exhibit 99.1 under Item 7.01 and is expressly stated as being furnished, not filed, which means it is not subject to certain liability provisions of the securities laws and is not automatically incorporated into other Securities and Exchange Commission documents.
Annexon, Inc. reported that it issued a press release outlining its 2026 strategic priorities and key milestones for its lead programs. The press release, titled “Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026,” focuses on advancing its next-generation targeted immunotherapy platform for neuroinflammatory diseases and highlights multiple planned registrational milestones in 2026. The full details are provided in the press release attached as Exhibit 99.1 to this report.
Annexon, Inc. director reports open-market stock purchase under a Rule 10b5-1 plan. On 12/01/2025, the reporting person bought 4,115 shares of Annexon common stock in a transaction coded as a purchase. The weighted average purchase price was $4.47 per share, with individual trades executed between $4.43 and $4.50.
After this transaction, the director beneficially owned 50,290 shares held directly. The filing notes that the trades were made pursuant to the director’s Rule 10b5-1 trading plan adopted on March 17, 2025, and the director has agreed to provide detailed trade information within the reported price range upon request.
Annexon, Inc. (ANNX) reported insider share purchases by director Muneer A. Satter through affiliated entities. On November 20, 2025, Alerce Medical Technology Partners, L.P. bought 400,000 shares of common stock at a weighted average price of $4.48. On November 21, 2025, Alerce Medical purchased an additional 422,613 shares at a weighted average price of $4.28. After these transactions, Satter is reported as beneficially owning 9,728,637 shares, held indirectly through a revocable trust, other trusts and entities, Satter Medical Technology Partners, L.P., and Alerce Medical, over which he has sole voting and dispositive power, while disclaiming beneficial ownership beyond his pecuniary interest.
Annexon, Inc. (ANNX) director reports sizable insider stock purchases. Over three consecutive days in November 2025, the reporting person, through Alerce Medical Technology Partners, L.P., bought 500,000 Annexon common shares on each of 11/17, 11/18, and 11/19.
The weighted average purchase prices were reported as $2.99, $3.18, and $3.94 for each respective day, with trades executed within stated price ranges. After these transactions, the reporting person beneficially owned 8,906,024 shares indirectly, including shares held in a revocable trust, various other trusts and entities, Satter Medical Technology Partners, L.P., and Alerce Medical, over which he has sole voting and dispositive power, subject to stated pecuniary interests.
Annexon, Inc. launched a primary offering of 25,096,153 shares of common stock and pre-funded warrants to purchase up to 3,750,000 shares, together with the shares issuable upon warrant exercise. The offering prices are $2.60 per share and $2.599 per pre-funded warrant, for gross proceeds of $74,996,247.80 and estimated net proceeds of about $69.9 million after fees and expenses.
The underwriters have a 30‑day option to buy up to 4,326,922 additional shares. Annexon plans to use proceeds to advance late‑stage programs, including tanruprubart in GBS and vonaprument in dry AMD with GA, and for working capital and general corporate purposes.
Pre-funded warrants have a $0.001 exercise price, do not expire, and include a 9.99% beneficial ownership limit (adjustable up to 19.99% with notice). Shares outstanding were 115,122,582 as of September 30, 2025, and are expected to be 140,218,735 immediately after this offering, assuming no exercise of pre-funded warrants.
Annexon, Inc. (ANNX) announced a primary offering of $75,000,000 of common stock, with the option for certain investors to purchase pre-funded warrants instead. The company also registered the shares issuable upon exercise of the pre-funded warrants. Underwriters have a 30‑day option to buy up to an additional $11,250,000 of common stock.
Pre-funded warrants will be sold at the share offering price minus $0.001 and have a $0.001 per share exercise price, are exercisable immediately, do not expire, and include a 9.99% Beneficial Ownership Limitation (adjustable up to 19.99% with 61 days’ notice). Annexon’s common stock trades on the Nasdaq Global Select Market under “ANNX”; the last reported sale price was $2.97 on November 11, 2025. Shares outstanding were 115,122,582 as of September 30, 2025; this is a baseline figure, not the amount being offered.
The company intends to use proceeds to advance its late‑stage neuroinflammation platform, led by global registrational programs tanruprubart in GBS and vonaprument in dry AMD with GA, and for working capital and other general corporate purposes. A 60‑day lock‑up applies, and sales under the existing 2024 ATM program are paused during this period.
Annexon, Inc. (ANNX) announced a primary offering of $75,000,000 of common stock, with the option for certain investors to purchase pre-funded warrants instead. The company also registered the shares issuable upon exercise of the pre-funded warrants. Underwriters have a 30‑day option to buy up to an additional $11,250,000 of common stock.
Pre-funded warrants will be sold at the share offering price minus $0.001 and have a $0.001 per share exercise price, are exercisable immediately, do not expire, and include a 9.99% Beneficial Ownership Limitation (adjustable up to 19.99% with 61 days’ notice). Annexon’s common stock trades on the Nasdaq Global Select Market under “ANNX”; the last reported sale price was $2.97 on November 11, 2025. Shares outstanding were 115,122,582 as of September 30, 2025; this is a baseline figure, not the amount being offered.
The company intends to use proceeds to advance its late‑stage neuroinflammation platform, led by global registrational programs tanruprubart in GBS and vonaprument in dry AMD with GA, and for working capital and other general corporate purposes. A 60‑day lock‑up applies, and sales under the existing 2024 ATM program are paused during this period.